Abstract
The effect of milk protein (MP) and milk protein hydrolysate (MPH) as Anti-diabetic agent were investigated in vivo using six groups of normal and type 2 diabetic rats. The results of this study showed that the treatments of diabetic rats by oral intake of MP or MPH significantly reduced the concentrations of plasma glucose, total lipids of blood plasma, triglycerides, total cholesterol, LDL and VLDL in rat plasma. Also, the treatments of diabetic rats by oral intake of MP or MPH significantly increased the globulin value and HDL, while the concentration of urea, creatinine and bilirubin were reduced. In addition, oral intake of MPH has no affective on acid phosphatase (ACP), alkaline phosphatase (ALP), alanine transaminase (ALT) and aspartate transaminase (AST) activities in blood plasma and liver of normal rats and protective its concentrations in diabetic rats. The present results concluded that MP and MPH could be used as anti-diabetic agents.
Highlights
Type 2 diabetes mellitus is a public health crisis that affects the economies of the world, especially developing countries
The present study aimed to investigate the biological effects of milk protein (MP) and milk protein hydrolysate (MPH) as anti-diabetic agents in alloxan-induced diabetic rats
Treatment with oral intake MP and MPH of diabetic rats was associated with plasma glucose concentrations significantly lower than those observed with control diabetic rats and higher than those observed with control non-diabetic rats
Summary
Type 2 diabetes mellitus is a public health crisis that affects the economies of the world, especially developing countries. The worldwide incidence of type 2 diabetes is increasing. It was estimated in 2000 that there were 171 million diabetics. In 2003 the expert committee of the American diabetes association proposed to eliminate the terms insulin and non-insulindependent diabetes mellitus and their acronyms (IDDM and NIDDM) [2]. Type 1 diabetes is known as IDDM [3]. Type 2 diabetes is a heterogeneous clinical syndrome characterized by elevated blood glucose levels due to defective insulin secretion and/or insulin action, so this type known as NIDDM [4]. When insulin secretion cannot compensate for insulin resistance, type 2 diabetes develops [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
